NFE2L2 and non-small cell lung carcinoma: However, clinical implementation of Nrf2 inhibitors in patients with advanced NSCLC may be a useful therapeutic approach for patients harboring KEAP1-NRF2 mutations, increasing the chance for clinical response (54, 55).